Northern Trust Corp Increases Position in Genmab A/S (NASDAQ:GMAB)

Northern Trust Corp grew its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 18.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 599,381 shares of the company's stock after purchasing an additional 94,858 shares during the period. Northern Trust Corp owned approximately 0.09% of Genmab A/S worth $12,509,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in Genmab A/S by 7.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock valued at $40,199,000 after purchasing an additional 139,722 shares during the last quarter. First Trust Advisors LP raised its position in shares of Genmab A/S by 18.0% during the 4th quarter. First Trust Advisors LP now owns 1,644,288 shares of the company's stock valued at $34,316,000 after buying an additional 251,241 shares in the last quarter. Brandywine Global Investment Management LLC bought a new stake in shares of Genmab A/S during the 4th quarter worth $33,804,000. Marshall Wace LLP grew its position in Genmab A/S by 162.2% in the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock worth $23,422,000 after acquiring an additional 694,243 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its position in Genmab A/S by 18,959.1% in the fourth quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company's stock worth $10,660,000 after acquiring an additional 508,104 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Price Performance

Genmab A/S stock traded up $0.30 during trading hours on Monday, reaching $20.18. The stock had a trading volume of 1,058,340 shares, compared to its average volume of 1,111,827. The company has a fifty day simple moving average of $19.74 and a 200-day simple moving average of $20.74. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $30.06. The stock has a market cap of $12.94 billion, a PE ratio of 11.60, a PEG ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The company had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Research analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on GMAB shares. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. HC Wainwright restated a "buy" rating and issued a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research report on Thursday, February 13th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.